ECOG-ACRIN NCORP Research Base

ECOG-ACRIN NCORP研究基地

• 批准号: 10461231
• 负责人: Peter J ODwyer
• 金额: $ 38.82万
• 依托单位: ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10461231
• 关键词: Adolescent and Young Adult; Adopted; Advocacy; Advocate; American College of Radiology Imaging Network; Area; Attention; Behavioral; Biological Markers; Biostatistical Methods; Breast Magnetic Resonance Imaging; Cancer Biology; Cancer Burden; Cancer Control; Cancer Prevention Trial; Cancer Research Network; Cancer Survivorship; Cardiotoxicity; Caring; Clinical; Clinical Research; Clinical Trials; Collaborations; Communities; Community Clinical Oncology Program; Complex; Continuity of Patient Care; Data Science; Development; Diagnosis; Discipline; Early Diagnosis; Eastern Cooperative Oncology Group; Elderly; Ensure; Fostering; Funding; Goals; Image; Immunooncology; Influentials; Infrastructure; Institution; International; Intervention; Laboratories; Leadership; Malignant Neoplasms; Measurement; Medical; Minority; Mission; Monitor; National Cancer Institute; National Clinical Trials Network; Nursing Research; Participant; Patient Outcomes Assessments; Patients; Physicians; Population; Population Heterogeneity; Postdoctoral Fellow; Prevention; Prevention strategy; Prevention trial; Primary Prevention; Process; Provider; Quality of life; Reporting; Research; Research Design; Research Personnel; Research Support; Resources; Risk; Science; Scientist; Screening for cancer; Secondary Prevention; Sexual and Gender Minorities; Site; Symptoms; System; Therapeutic Trials; Tissue imaging; Translating; Translational Research; Underrepresented Minority; Underserved Population; Work; advanced disease; anticancer research; base; biobank; biomarker-driven; cancer care; cancer clinical trial; cancer prevention; cancer therapy; care delivery; career development; control trial; eHealth; ethnic minority population; experience; financial toxicity; health equity; health related quality of life; high risk; high risk population; imaging biomarker; imaging modality; improved; individualized prevention; innovation; interest; member; multidisciplinary; novel; novel marker; oncology program; operation; overtreatment; personalized approach; physical symptom; precision oncology; prevent; programs; psychological symptom; racial minority; research study; rural dwellers; screening; support network; survivorship; symptom science; tissue biomarkers

Project Summary The ECOG-ACRIN Cancer Research Group (EA) is dedicated to decreasing the burden of cancer. EA is a vibrant member of the National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP), focused on practice-changing clinical and translational research across the cancer care continuum from prevention and early detection, through the management of advanced disease and its impact. As an NCORP Research Base, EA has engaged community providers and researchers to develop a robust research portfolio that spans Cancer Prevention, Cancer Control, and Cancer Care Delivery, aligned with the overall scientific themes of precision oncology, immuno-oncology, reducing overdiagnosis and overtreatment, and leveraging novel biomarker platforms. Cancer control trials examine and intervene on challenges associated with cancer and treatment-related symptoms and concerns. EA's portfolio of therapeutic trials yield opportunities to apply patient-reported outcomes measurement science to quantify health-related quality of life, symptoms, and domains most relevant to patients in the context of evolving treatment paradigms. Behavioral and biomarker-driven symptom interventions aim to improve quality of life and cancer survivorship. Cardiotoxicity research aims to mitigate risk through quantifying cardiotoxicity associated with treatment, identifying groups at risk, and advancing interventions to reduce risk. Prevention trials embrace the NCI's broad definition of prevention to include primary prevention, cancer screening, and secondary prevention and aim to identify high risk groups for precision prevention strategies. Cancer Care Delivery Research (CCDR) examines the complex interactions between patient, provider, and system factors that influence care, and adapts and evaluates interventions in heterogenous community oncology practices. Health equity research permeates EA science through embedding disparities-related research questions that span EA activities, adopting a broad view of underserved populations including adolescents and young adults, the elderly, racial and ethnic minorities, sexual and gender minorities and rural residents. Key collaborations with community-based oncology programs will ensure access to EA NCTN and NCORP trials in communities where patients receive their care. EA provides access to existing NCI-funded resources and a network of >10000 physicians, scientists, nurses, research associates (RAs), statisticians, biomedical information technologists, and patient advocates across approximately 600 institutions and organizations. EA has provided scientific leadership in the NCORP community through advancing rigorous, practice-changing clinical trials and translational research in cancer control, prevention and care delivery and is well poised to continue to support the NCI's mission to engage community-based diverse populations in cancer research.

项目总结